Monoclonal antibody againstv-integrins (options), receive (options) and use hybridoma, polypeptide, dna

 

The invention relates to immunobiotechnology and applies to new monoclonal antibodies, methods for their production using hybridoma technology and our-integrin or vitronectin as antigens, polypeptides, representing light and heavy chains of the antibody and DNA encoding these polypeptides. The possibility of using antibodies in the form of pharmaceutical compositions for the treatment of tumors, in particular melanoma, as well as for the diagnosis and localization of tumor growth. Monoclonal antibody, in particular A, has the following properties: interacts withV-chainV-integrins man, blocking the attachment of cells containingV-integrins to the substrate integrins, violates the established interaction cell-matrix, calledV-integrins, blocks tumor growth and did not show cytotoxic activity. Using new monoclonal antibodies can block the functions of integranova chain person and, as a consequence, the development of tumors. 11 C. and 3 h.p. f-crystals, 52 ill., 3 table.

Description text in facsimile form (see graphic part).

V-chainV-integrins man, blocking the attachment of cells containingV-integrin, to the substrate integrin violates the established interaction cell-matrix, calledV-integrins, blocks tumor growth and did not show cytotoxic activity, which contains the amino acid sequence encoded by the DNA nucleotide sequence which corresponds to the open reading frame regions FR and complementarity determining regions (CDRs) of the light chain position 21-127 in Fig. 17A, corresponding to amino acids 21-127 sequence SEQ ID No. 1 and the heavy chain position 20-137 of Fig. 17b, corresponding to amino acids 1-118 of the sequence SEQ ID No. 9.

2. Monoclonal antibody under item 1, characterized in that the substrate integrin is vitronectin, fibronectin or fibrinogen.

3. Monoclonal antibody under item 1, characterized in that it blocks the development of melanoma.

4. Hybridoma cell line 2-72-E, deposited under number DSM ASS, capable of producing a monoclonal antibody according to PP. 1-3.

5. Monobloc by p. 4.

6. The polypeptide having the amino acid sequence encoded by the DNA corresponding to the open reading frame regions FR, complementarity determining regions (CDRs) of the light chain position 21-127 in Fig. 17A, corresponding to amino acids 21-127 sequence SEQ ID No. 1.

7. The polypeptide having the amino acid sequence corresponding to the regions 20-137 of Fig. 17b heavy chain, and which corresponds to amino acids 20-137 of the sequence SEQ ID No. 9.

8. The DNA sequence having the nucleotide sequence corresponding to the open reading frame regions FR, and encoding the polypeptide under item 6.

9. The DNA sequence having the nucleotide sequence corresponding to the open reading frame regions FR, and encoding the polypeptide under item 7.

10. Pharmaceutical composition for treating tumors containing monoclonal antibody according to any one of paragraphs. 1-3 and 5, and a pharmaceutically acceptable carrier.

11. Pharmaceutical composition, characterized in p. 10 used as a diagnostic tool to establish the localization and growth of tumors, preferably melanoma.

12. The method of obtaining monoclonal antibodies chr/8226.gif">V3-integrin, selected by the method of ELISA clones to bind to the purifiedV3-receptor, and receive specific hybridoma cell line producing the specified monoclonal antibody.

13. The method according to p. 12, characterized in that said integrin is the receptor for vitronectin.

14. The method of obtaining monoclonal antibodies, as described in paragraph 5, characterized in that mice subjected to immunization with purified vitronectin, selected by the method of ELISA clones binding to the purified receptor for vitronectin, and get a hybridoma cell line described in paragraph 4, producing the specified monoclonal antibody.

 

Same patents:

The invention relates to medicine, in particular for the diagnosis of metabolic bone diseases

The invention relates to medical biotechnology and is concerned with the obtaining of monoclonal antibodies (MAB) and its fragments using hybridoma FERM BR-4382, which produces the above-mentioned antibody

The invention relates to the field of veterinary Virology, in particular to a method for the diagnosis of sheep pox and goat
The invention relates to immunology and medicine and can be used for immunotherapy of malignant tumors

The invention relates to biotechnology, in particular to antibodies against Rtln, obtained by genetic engineering methods

The invention relates to the field of biotechnology and medicine, specifically to the diagnosis of opisthorchiasis

The invention relates to veterinary Virology, in particular to a method for the diagnosis of sheep pox and goat pox

The invention relates to veterinary Virology and biotechnology

The invention relates to immunology and can be used to generate antibodies, the diagnosis of autoimmune diseases and the treatment of rheumatoid arthritis

The invention relates to the field of veterinary biotechnology and can be used to produce hybrid strain of cultured cells producing monoclonal antibodies (M-at) to antigens of Chlamydia
The invention relates to biotechnology and medicine and can be used to identify proliferating cells

The invention relates to hybrid technology and can be used in veterinary medicine and medicine in the diagnosis of brucellosis

The invention relates to medical biotechnology and is concerned with the obtaining of monoclonal antibodies (MAB) and its fragments using hybridoma FERM BR-4382, which produces the above-mentioned antibody
Up!